http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20070051909-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b2710fc436b8878c41e7b12250bba5a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e61263b84630539d1fc5281e3bd9ac4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-90 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-02 |
| filingDate | 2005-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_799b9d10b6d3f57722a204d60d1b9d45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5df4299c876da790fb86acce21a841e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_893f28f6e34f1cb26ae21c7e51c089b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9ca3e3425d2595b156b0628bc7e9f27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1ed26ecc98ea756d0a37d9a8cc0e308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93f47710e3c298f14fec30c5829bec2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e846555ee4a2b63439accf16ded8df5 |
| publicationDate | 2007-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20070051909-A |
| titleOfInvention | Fibrate Compounds Having PAPR Antagonist Activity |
| abstract | Derivatives having PPAR antagonist activity are provided. This derivative comprises a compound of formula (I) and / or a pharmaceutically acceptable salt of this compound:n n n (I)n n n In the formula,n n n A is Has a structure of; X is selected from -CH 2- , -O-, -NH- and -S-; Y is selected from -O-, -NH- and -S-; Z, which may be present at the substituted position, is hydrogen or halogen; R 1 and R 2, which may be the same or different, are independently selected from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 combine to form a carbocyclic ring having 4 to 6 carbon atoms; R 3 is selected from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 and R 6 , which may be the same or different, are selected from hydrogen and C 1 -C 8 alkyl; And n is 1 to 6; Various embodiments and variations are provided. According to another aspect, the present invention provides a method for producing PPARα antagonist activity in a mammal comprising administering to the mammal an effective amount of the specific derivative according to the first aspect, the mammal comprising administering to the mammal an effective amount of the specific derivative. A method of producing PPARα antagonist activity and PPARγ antagonist activity in an animal, a derivative according to the first aspect of the invention and a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients. Various embodiments and variations are provided.n n n PPARα antagonist activity, PPARγ antagonist activity, pharmaceutical compositions, mammals |
| priorityDate | 2004-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.